IMV News and Press, IMV Inc. From 10/08/20

Selected for additional funding by Canadian Government bringing total support to $10M for clinical development and manufacturing of DPX-COVID-19 Clinical plan updated to run a larger Phase 1/2 study with the goal to expedite later-stage development Collaboration initia...

Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine. Investors are awaiting the publication of the clinical Phase 1 results. Amid daily vaccine news hitting the market, it is important to be realistic about the opportunit...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, today announced that company’s Chief Executive Officer, Frederic Ors will participate at the Vaccines Panel of the 20...

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the IMV’s executive management team wi...

IMV Inc. (IMV) Q2 2020 Earnings Conference Call August 12, 2020 08:00 AM ET Company Participants Pierre Labbé - CFO Frederic Ors - CEO Joanne Schindler - CMO Conference Call Participants Jim Birchenough - Wells Fargo Securities Ted Tenthoff - Piper Sandler Joe Pant...

IMV (NASDAQ: IMV ) : Q2 GAAP EPS of -C$0.13. More news on: IMV Inc., Earnings news and commentary, Read more ...

Rapidly progressing DPX-COVID-19, including Health Canada agreement on Phase 1 clinical study design protocol, with preliminary results expected in fall 2020 Confirmed $4.75M of non-dilutive fund supporting Phase 1 clinical development of DPX-COVID-19 Updated data from ...

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...